The scale of the problem these researchers address is staggering. A landmark 2022 analysis published in The Lancet estimated that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths in 2019 and contributed to 4.95 million deaths worldwide. The economic toll is equally alarming, with projections suggesting that without effective intervention, drug-resistant infections could cost the global economy up to 100 trillion US dollars by 2050. The economic burden is already measurable at national levels—a study of inpatient care in China estimated that antibiotic resistance costs the healthcare system there more than 6 billion dollars annually. These figures underscore an uncomfortable reality: the antibiotic pipeline has slowed to a trickle while resistance mechanisms continue to proliferate through horizontal gene transfer, the process by which bacteria share resistance genes across species boundaries via plasmids and other mobile genetic elements.

What makes conventional antibiotics vulnerable is their fundamentally narrow mechanism of action. Most classical antibiotics target a single molecular process—cell wall synthesis, protein translation, DNA replication, or folate metabolism. This creates a powerful selective pressure: a single mutation in the target site, acquisition of a drug-inactivating enzyme, or upregulation of an efflux pump can render the entire therapeutic useless. The Arak University review identifies four primary resistance pathways that bacteria employ. Efflux pumps, membrane-spanning transport proteins belonging to families such as the resistance-nodulation-division (RND) superfamily and the major facilitator superfamily (MFS), actively expel antibiotics from the bacterial cytoplasm before they can reach lethal concentrations. Enzymatic degradation, exemplified by extended-spectrum beta-lactamases (ESBLs) and the New Delhi metallo-beta-lactamase (NDM), chemically destroys or modifies antibiotic molecules. Target site modification alters the bacterial structures that antibiotics must bind, as seen with penicillin-binding protein 2a (PBP2a) in methicillin-resistant Staphylococcus aureus (MRSA). Finally, biofilm formation—where bacteria encase themselves in a protective extracellular polymeric substance (EPS)—creates physical and metabolic barriers that can reduce antibiotic penetration by orders of magnitude and slow bacterial growth to a state of dormancy where most antibiotics are ineffective.

Metal nanoparticles operate on an entirely different principle. Rather than targeting a single molecular entity, they attack bacteria through multiple simultaneous mechanisms that would require a pathogen to evolve resistance at numerous points at once. The review details three primary modes of nanoparticle-mediated killing. The first involves direct physical disruption of the bacterial cell membrane. Silver nanoparticles and zinc oxide nanoparticles can interact with the lipid bilayer through electrostatic attractions and van der Waals forces, causing membrane depolarization, increased permeability, and ultimately cellular rupture. Research cited in the review demonstrates that positively charged sites on iron oxide nanoparticles interact with negatively charged bacterial membranes, generating sufficient mechanical stress to stretch and tear the membrane beyond repair—a mechanism so fundamentally physical that bacteria have no known genetic countermeasure.

The second mechanism involves the generation of reactive oxygen species (ROS), a cascade of highly reactive molecules including superoxide radicals, hydrogen peroxide, and hydroxyl radicals that overwhelm cellular antioxidant defenses. When metal nanoparticles contact bacterial cells, they catalyze redox reactions that produce these destructive molecules. The review explains that ROS inflict damage on DNA—detected as 8-hydroxy-2′-deoxyguanosine adducts—lipids, producing malondialdehyde, and proteins, generating 4-hydroxynonenal modifications. Bacterial antioxidant enzymes like superoxide dismutase, catalase, and glutathione peroxidase can neutralize normal levels of ROS, but the overwhelming flux generated by nanoparticles exceeds their capacity, leading to irreversible oxidative damage and cell death. Gold nanoparticles can even amplify this effect through plasmonic excitation, where light absorption generates hot electrons that accelerate ROS formation.

The third and perhaps most clinically significant mechanism involves the modulation of bacterial gene expression. Here, the review presents evidence that nanoparticles do not simply kill bacteria—they can specifically silence the genes that enable resistance in the first place. Multiple studies document how various nanoparticles downregulate efflux pump genes. Biosynthesized iron oxide-silver nanocomposites have been shown to suppress expression of norA and norB efflux pump genes in ciprofloxacin-resistant Staphylococcus aureus, effectively restoring the bacterium’s susceptibility to fluoroquinolones. Gold nanoparticles evaluated against clinical isolates from burn patients similarly reduced NorA and NorB expression. In Acinetobacter baumannii, biologically synthesized silver nanoparticles demonstrated efflux pump inhibitory activity against multidrug-resistant clinical isolates, and ursolic acid-conjugated magnetic nanoparticles enhanced antimicrobial and anti-biofilm effects against multidrug-resistant Pseudomonas aeruginosa.

Perhaps even more remarkably, nanoparticles can disrupt quorum sensing—the chemical communication system that coordinates bacterial virulence behaviors and biofilm formation. The review cites studies showing that phyto-synthesized silver nanoparticles inhibit quorum sensing in Pseudomonas aeruginosa, suppressing virulence factor production and biofilm formation. Zinc oxide nanoparticles biosynthesized from Origanum vulgare (oregano) abrogated quorum sensing and biofilm formation in Chromobacterium violaceum. Titanium dioxide nanoparticles reduced expression of both efflux pump and quorum-sensing genes in multidrug-resistant Pseudomonas aeruginosa isolates. This anti-virulence approach is particularly attractive because it does not exert direct bactericidal pressure, potentially reducing the evolutionary incentive for resistance development.

The authors also highlight nanoparticles’ ability to suppress biofilm-related gene expression directly. Functionalized iron oxide nanoparticles conjugated with thiosemicarbazide were shown to decrease expression of icaA and icaD genes—which encode enzymes responsible for polysaccharide intercellular adhesin production—in methicillin-resistant Staphylococcus aureus. These genes are central to the biofilm matrix architecture, and their suppression effectively prevents the formation of the protective bacterial fortress that makes infections so difficult to eradicate. Additionally, certain nanocomposites including iron oxide combined with molybdenum disulfide have been shown to block horizontal gene transfer itself, preventing the conjugative spread of antibiotic resistance genes between bacterial cells—a capability that no conventional antibiotic possesses.

Beyond their intrinsic antimicrobial properties, metal nanoparticles serve as versatile platforms for advanced functionalization strategies that enhance their specificity and potency. The review describes organic ligand conjugation approaches where antimicrobial compounds such as kanamycin, levofloxacin, gallic acid, and ursolic acid are tethered to nanoparticle surfaces, creating hybrid systems that deliver concentrated payloads directly to bacterial cells. Gold nanoparticles conjugated with kanamycin exhibited potent antibacterial activity with a novel mechanism involving membrane depolarization. Antibody-nanoparticle conjugates represent another frontier—by attaching monoclonal antibodies to nanoparticle surfaces, researchers can direct these weapons to specific pathogens with molecular precision. One study demonstrated that ICAM-1 antibody-conjugated nanoparticles modified with D-alpha-tocopheryl polyethylene glycol succinate achieved targeted therapy against drug-resistant infections.

Green synthesis approaches receive substantial attention in the review as environmentally sustainable alternatives to chemical nanoparticle production. By using plant extracts, microbial cultures, and biological waste materials as reducing and capping agents, researchers can produce nanoparticles with well-defined sizes and shapes while avoiding toxic chemical byproducts. Plant-derived synthesis of gold nanoparticles using Coleus aromaticus leaf extract, zinc oxide nanoparticles from Brassica oleracea (cauliflower) leaf extract, and silver nanoparticles from probiotic Lactobacillus rhamnosus all demonstrated significant antimicrobial activity. These biologically synthesized nanoparticles often carry intrinsic bioactive molecules on their surfaces that contribute additional therapeutic effects, essentially combining green chemistry with pharmacology in a single nanoscale construct.

Despite these remarkable capabilities, the review is candid about the translational barriers that stand between laboratory promise and clinical reality. Cytotoxicity remains the paramount concern—many metal nanoparticles that kill bacteria can also damage mammalian cells, particularly through the same ROS-mediated mechanisms that make them effective antimicrobials. The pharmacokinetic profile of nanoparticles is often unpredictable, with questions about absorption, distribution, metabolism, and excretion (ADME) that differ fundamentally from conventional small-molecule drugs. Standardized manufacturing protocols are urgently needed to ensure batch-to-batch consistency, as nanoparticle biological activity depends critically on size, shape, surface charge, and coating—parameters that can vary significantly between synthesis methods. The review notes that while antimicrobial coatings for medical devices, wound dressings, and topical formulations represent the nearest-term clinical applications, systemic nanoparticle therapy will require more sophisticated engineering to achieve therapeutic windows that spare host tissues.

Looking forward, the review identifies several emerging directions that could define the next decade of nanoparticle-based antimicrobial research. Environmentally responsive “smart” nanoparticles that activate specifically in the presence of bacterial signals or the acidic conditions of infection sites could minimize off-target toxicity. Nanoparticle-mediated delivery of small interfering RNA (siRNA) to selectively silence resistance genes within bacterial cells represents a gene-silencing approach that could restore susceptibility to existing antibiotics without requiring new drug development. Integration of multi-omics approaches—including transcriptomics, proteomics, and metabolomics—offers the potential to decode the complete molecular conversation between nanoparticles and bacterial cells, revealing unexpected resistance mechanisms and optimizing nanoparticle designs with unprecedented precision. As the authors conclude, the convergence of these approaches positions engineered metal nanoparticles not merely as an alternative to antibiotics but as an entirely new therapeutic paradigm that could finally turn the tide against the growing threat of untreatable infections.